"Mixed" new crown vaccines are more effective, and immunity can be maintained for at least 1 year after infection with new crowns. Progress in research on new crowns for one week

The uniqueness of the nasal spray vaccine to defend against the "first line" of the new crown virus invasion

The uniqueness of the nasal spray vaccine to defend against the "first line" of the new crown virus invasion

Recently, an article published on the C&EN website under the American Chemical Society discussed the advantages and disadvantages of intranasal vaccines
.

The article pointed out that compared with injection vaccines, nasal spray vaccines have the potential to prevent new coronaviruses from invading the human body at the first line of invasion

Although the currently developed injectable new crown vaccine can effectively stimulate the body's antibody and cellular immune response, they cannot effectively stimulate the mucosal immune response
.

The advantage of the nasal spray vaccine is that in addition to stimulating the systemic antibody and cellular immune response, it can also stimulate the mucosal immune response, thereby providing more comprehensive immune protection
.

"Mixed" new crown vaccine is better

"Mixed" new crown vaccine is better

At present, most of the new crown vaccines approved for marketing in the world require two doses, and three recent studies have shown that the two vaccines use vaccines produced by different manufacturers, that is, "mixed vaccines", which has better epidemic prevention effects
.

The analysis found that the IgG antibody in the blood of the mixed vaccine was 30 to 40 times higher than that of the control group who received only one dose of AstraZeneca
.

At the same time, the level of neutralizing antibodies in the body of those who received the Pfizer vaccine in the mixed vaccine increased seven-fold.

In the current shortage of new crown vaccines, if the mixed vaccine proves to be safe and effective, it will help accelerate the vaccination work
.

Researchers clarify the escape mechanism of the neutralizing antibody of the new coronavirus mutant

Researchers clarify the escape mechanism of the neutralizing antibody of the new coronavirus mutant

On June 8, researchers published an article in the journal Immunity, which confirmed the effect of multiple mutation sites in the spike glycoprotein of mutant virus strains on the escape of neutralizing antibodies and the use of ACE2 in different species.
Mutant strains pose a severe challenge to current antibody therapy and vaccine protection
.

Release of vaccine's real-world protection against second-generation Indian mutant strains

Release of vaccine's real-world protection against second-generation Indian mutant strains

On June 14, "The Lancet" published a blockbuster article by the University of Edinburgh, reporting that inoculation of AstraZeneca and Pfizer/BioTech vaccines in Scotland is effective in preventing the Delta mutant (the second-generation Indian mutant B.
1.
617).
.
2) Real-world protection
.

The study analyzed 19,543 SARS-CoV-2 infection cases and 377 hospitalized medical records of the EAVE II system from April 1 to June 6 this year, and pointed out that the protective power of vaccination appeared 28 days after the first dose.
The study used S gene positive PCR to identify mutant and non-mutant infections, and found that the protection of two doses of Pfizer/BioTech vaccine against non-mutant strains was 92%, and the protection against mutant strains was 79%
.

AstraZeneca vaccine has 73% protection against non-mutant strains and 60% protection against mutant strains

The phase 3 clinical results of the recombinant protein new crown vaccine candidate are positive, and the protection can reach more than 90%

The phase 3 clinical results of the recombinant protein new crown vaccine candidate are positive, and the protection can reach more than 90%

On June 14, Novavax announced that its recombinant protein-based nanoparticle new crown vaccine candidate NVX-CoV2373 has reached the primary endpoint in a pivotal phase 3 clinical trial, with an overall protective efficacy of 90.
4%
.

In addition, its protection against moderate and severe COVID-19 is 100%, and its effectiveness in high-risk groups is 91%
.

Moreover, NVX-CoV2373 also showed good protective effect on the main concern mutant (VoC)/mutant to be observed (VoI)

Immunity can be maintained for at least 1 year after being infected with the new crown

Immunity can be maintained for at least 1 year after being infected with the new crown

According to the latest article published on the website of the journal Nature on the 14th, scientists studied 63 individuals who had been infected with the new coronavirus and recovered and found that their immunity to the new coronavirus still exists 12 months after being infected
.

Among them, the immunity of those who have been vaccinated will be further improved, which is about 50 times higher than before

Latest U.

Latest U.

Studies have found that the coronavirus spread in the United States as early as December 2019, about a month before the first confirmed case of new coronary pneumonia was reported in the United States, and it was also earlier than the official discovery of the coronavirus in China

The new crown neutralizing antibody combination reduces the mortality rate of specific hospitalized patients by 20% in phase 3

The new crown neutralizing antibody combination reduces the mortality rate of specific hospitalized patients by 20% in phase 3

On June 16, Regeneron announced that its research neutralizing antibody therapy REGEN-COV (casirivimab and imdevimab) has obtained positive preliminary results in the Phase 3 clinical trial RECOVERY

The results of the test showed that among COVID-19 hospitalized patients who did not have a natural antibody response to the new coronavirus, the addition of REGEN-COV on the basis of routine care can reduce the risk of death by 20% compared with the control group

Leave a message here